Raymond Hakim
Last active: 6/9/2014

Kinetics and efficacy of deferoxamine in iron-overloaded hemodialysis patients.

Stivelman J, Schulman G, Fosburg M, Lazarus JM, Hakim RM
Kidney Int. 1989 36 (6): 1125-32

PMID: 2601259 · DOI:10.1038/ki.1989.311

We evaluated the kinetics and efficacy of deferoxamine (DFO) therapy in iron-overloaded hemodialysis patients. Concentrations of DFO and its chelated product, feroxamine (Fx), were assessed following single-dose DFO administration in twelve patients, and during chronic therapy over one year's time in eight, similarly iron-overloaded dialysis patients. A functional assay which relies on measurements of iron and iron binding capacity for the determination of Fx and DFO, respectively, was corroborated with liquid chromatographic techniques. Half-life measurements were also corroborated with tracer doses of 14C-DFO and 59Fe-feroxamine. Intradialytic DFO half-life (2.3 +/- 1.1 h) was considerably less than interdialytic half-life (26 +/- 1 hr). Unbound DFO was found to persist throughout the interdialytic period. Calculation of the percent saturation of the DFO dose indicated that only 30% of a given dose is chelated. The amount of iron removed dialytically was approximately 13.1 +/- 2.7 mg per dialysis session. Chronic DFO administration was also shown to enhance gastrointestinal iron excretion threefold. However, ferritin levels decreased by only 25% after one year of thrice-weekly DFO therapy. We conclude that DFO therapy for iron-overloaded hemodialysis patients is optimized by its administration interdialytically, and results in slow removal of iron, via both dialytic and gastrointestinal routes.

MeSH Terms (11)

Adult Deferoxamine Female Ferric Compounds Humans Iron Iron Chelating Agents Male Middle Aged Renal Dialysis Time Factors

Connections (1)

This publication is referenced by other Labnodes entities: